Germany's Merck suffers setback with cancer drug

December 19, 2012

German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.

The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.

shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.

The company is a separate entity from Merck & Co., which is based in the U.S.

Explore further: Merck KGaA suffers setback on cancer drug

shares

Related Stories

Merck KGaA suffers setback on cancer drug

July 5, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Merck KGaA suffers setback for cancer drug

September 18, 2012

German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.

Recommended for you

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

Nearly 1 in 3 on Medicare got commonly abused opioids

June 22, 2016

Nearly 12 million Medicare beneficiaries received at least one prescription for an opioid painkiller last year at a cost of $4.1 billion, according to a federal report that shows how common the addictive drugs are in many ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.